Modeled impact of intensified PSA screening in Black men

This dataset contains total prostate cancer diagnoses, screen diagnoses, and overdiagnoses per 1000 men under no screening and historical early detection strategies for all races and under no screening, historical, and intensified early detection strategies (by varying screening intervals, starting and stopping ages, and biopsy utilization following an abnormal PSA) for Black men in the United States projected by two models: the Fred Hutchinson Cancer Research Center ("FHCRC") and Erasmus Medical Center MIcrosimulation SCreening ANalysis ("MISCAN") models. The dataset also contains the estimated mean lead time ("MLT") for each early detection strategy and the estimated prostate cancer mortality reduction with 95% confidence intervals based on a combined analysis of the European Randomized Study of Screening for Prostate Cancer and the US-based Prostate, Lung, Colorectal, and Ovarian cancer screening trial.